Prestige Consumer Healthcare Inc. $PBH is Ariel Investments LLC's 9th Largest Position

Key Points

• Ariel Investments LLC reduced its stake in Prestige Consumer Healthcare Inc. by 8.8%, now holding approximately 2.5% of the company, valued at $216.55 million.
• Prestige Consumer Healthcare reported a net loss of $0.95 EPS for the last quarter, missing estimates and showing a revenue decline of 6.6% year-over-year.
• Wall Street analysts have mixed opinions on the stock, with three analysts rating it a "Buy" and three a "Hold," and a decreased target price of $100.00 from Canaccord Genuity Group.

Ariel Investments LLC lowered its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 8.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,518,941 shares of the company's stock after selling 243,082 shares during the period. Prestige Consumer Healthcare makes up about 2.5% of Ariel Investments LLC's holdings, making the stock its 9th biggest position. Ariel Investments LLC owned about 5.08% of Prestige Consumer Healthcare worth $216,553,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of PBH. Tower Research Capital LLC TRC raised its position in shares of Prestige Consumer Healthcare by 97.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,925 shares of the company's stock valued at $150,000 after purchasing an additional 950 shares during the period. Susquehanna International Group LLP raised its position in shares of Prestige Consumer Healthcare by 118.1% in the fourth quarter. Susquehanna International Group LLP now owns 21,189 shares of the company's stock valued at $1,655,000 after purchasing an additional 11,475 shares during the period. Tudor Investment Corp ET AL bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $1,315,000. Northern Trust Corp raised its position in shares of Prestige Consumer Healthcare by 10.9% in the fourth quarter. Northern Trust Corp now owns 813,076 shares of the company's stock valued at $63,493,000 after purchasing an additional 80,055 shares during the period. Finally, Lido Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $226,000. Institutional investors own 99.95% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on PBH. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Zacks Research lowered shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a report on Thursday. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of "Hold" and an average target price of $93.33.

Prestige Consumer Healthcare Trading Down 2.5%

PBH traded down $1.69 during trading on Friday, hitting $65.06. 693,488 shares of the stock traded hands, compared to its average volume of 617,635. The firm has a market capitalization of $3.20 billion, a P/E ratio of 15.27, a price-to-earnings-growth ratio of 2.06 and a beta of 0.46. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The firm has a 50-day moving average of $72.04 and a 200 day moving average of $79.90. Prestige Consumer Healthcare Inc. has a 12-month low of $62.95 and a 12-month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. During the same period in the previous year, the company earned $0.90 EPS. The company's quarterly revenue was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.